Technivie (ombitasvir, paritaprevir, and ritonavir)
When is Technivie contraindicated?
UPDATE: AbbVie discontinued Technivie effective December 31, 2018.
Technivie is contraindicated in patients with severe hepatic impairment, when co-administered with drugs that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events, specific types of medication (see below), and those with a known hypersensitivity to ritonavir.
For those taking Technivie in combination with ribavirin the contraindications to ribavirin will also apply to this combination treatment. Therefore, this treatment is contraindicated in pregnant women or those that may become pregnant as well as men whose female partner is pregnant, due to the risks for birth defects and fetal death associated with ribavirin. For more specific information, refer to the prescribing information for ribavirin for a list of all contraindications.
The following chart provides information regarding potentially significant drug interactions with Technivie (the table is not all-inclusive). Alteration in dose or regimen may be recommended based on drug interaction studies or predicted interactions. (For more information regarding the effect of co-administration of these medications with Technivie and recommendations for alterations in dose or regimen please visit www.Technivie.com.)
|Drug Class||Specific Drugs Within Class Contraindicated with Technivie|
|Alpha1-Adrenoreceptor Antagonist||Alfuzosin HC1|
|Ethinyl Estradiol-Containing Products||Ethinyl Estradiol-Containing Medications such as combined oral contraceptives|
|Herbal Products||St. John’s Wort|
|HMG-CoA Reductase Inhibitors||Lovastatin
|Non-Nucleoside Reverse Transcriptase Inhibitor||Efavirenz|
|Phophodiesterase-5 (PDE5) Inhibitor||Sildenafil when dosed as Revatio for the treatment of pulmonary arterial hypertension (PAH)|
Orally administered Midazolam
Last Updated: December 2018
Bristol-Myers wins approval for 1st hepatitis C type 3 drug. http://www.washingtontimes.com/news/2015/jul/24/bristol-myers-wins-approval-for-1st-hepatitis-c-ty/, The Washington Times. Retrieved July 28, 2015.
Highlights of Prescribing Information - TECHNIVIE. http://rxabbvie.com/pdf/technivie_pi.pdf, AbbVie, Inc. Retrieved July 28, 2015.